RNA Projected Dividend Yield
Avidity Biosciences Inc ( NASDAQ : RNA )Avidity Biosciences is a biopharmaceutical company developing a new class of RNA therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. Co.'s lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare monogenic muscle disease. Co. pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy. 20 YEAR PERFORMANCE RESULTS |
RNA Dividend History Detail RNA Dividend News RNA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |